Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorThe First Affiliated Hospital with Nanjing Medical University
About this trial
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
Eligibility criteria
Qualifiers
18-75 years old.
Clinical diagnosis of calciphylaxis, including patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis).
All subjects signed informed consent.
Disqualifiers
Patients who refuse to sign informed consent.
Patients with malignant tumors or severe psychiatric disorders, or an expected survival time of less than 6 months.
Pregnant or lactating women of childbearing age.
Participation in another clinical trial with an experimental drug within 90 days prior the inclusion.
Trial design
Treatments tested in this trial
- Human amniotic-derived mesenchymal stem cells
Treatment groups
9 Participants
are divided into 1 treatment groupSponsors and collaborators
The First Affiliated Hospital with Nanjing Medical University
Lead sponsor
Westlake University
Collaborator
Source ClinicalTrials.gov